Global Depression Drugs Market - A Report by Fact.MR
Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global depression drugs market. The depression drugs market report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth. Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the depression drugs market report elaborates the market behavior of each vendor operating in the depression drugs market.
The depression drugs market report considers the following years to present the overall market growth:
- Estimated Year: 2026
- Forecast Year: 2018 – 2026
Key findings of the depression drugs market study:
- Regional breakdown of the depression drugs market based on predefined taxonomy.
- Innovative manufacturing processes implemented by depression drugs market vendors in detail.
- Region-wise and country-wise fragmentation of the depression drugs market to grasp the revenue, and growth outlook in these areas.
- Changing preferences among consumers across various regions and countries.
- Factors (Positive and Negative) impacting the growth of the global depression drugs market.
On the basis of disease type, the depression drugs market study consists of:
- Major Depressive Disorder
- Schizophrenia and bipolar I disorder (manic depression)
- SSRI induced
Request Methodology of this Report - https://www.factmr.com/connectus/sample?flag=RM&rep_id=3215
On the basis of drug class, the depression drugs market study incorporates:
- Atypical antipsychotics
- Serotonin-norepinephrine reuptake inhibitors
- Selective serotonin reuptake inhibitors
- CNS stimulants
On the basis of region, the depression drugs market study contains:
- North America (U.S., Canada)
- Latin America (Brazil, Mexico)
- Europe (U.K., Nordic)
- Middle East and Africa (South Africa, Turkey)
Key players analyzed in the depression drugs market study:
- Johnson and Johnson
- Sebela Pharmaceutical Inc.
- Takeda Pharmaceutical Company Ltd.
- GlaxoSmithKline
- Novartis AG
- Allergan USA Inc.
- AstraZeneca, Pfizer Inc.
- Eli Lilly and Company
- Otsuka Pharmaceutical Co., Ltd.
- Alkermes Plc,
- Bristol Myers Squibb Co.
- Lundbeck
- Teva Pharmaceutical Industries Ltd
Queries addressed in the depression drugs market report:
- Why are the depression drugs market players targeting region for increased product sales?
- What patented technologies are the players utilizing in the global depression drugs market?
- Which regions are displaying the fastest growth in the depression drugs market?
- What are the underlying micro- macroeconomic factors affecting the global depression drugs market?
Request Sample Report - https://www.factmr.com/connectus/sample?flag=S&rep_id=3215
Why choose Fact.MR?
Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.
The depression drugs market, valued at over US$ 6.5 billion in 2017, is likely to witness bearishness in the near future, with a new report by Fact.MR estimating revenues to decline at a -2% CAGR.
According to the study, although the prevalence rate of depression has gone up in the last decade, preference for cognitive behavior therapy (CBT) and awareness about the potential side effects has led to a decline in demand for depression drugs.
The study finds that US continued to be at the forefront in terms of total depression drugs sold in 2018.According to the World Health Organization (WHO), depression has become one of the common illnesses, affecting over 300 million people across the world.
In the United States, approximately 10.3 million adults had experienced at least one major depressive episode that resulted in severe impairment, according to the National Institute of Mental Health (NIMH).
High prevalence of such depressive episode was observed among people aged 18-25 (10.9%), female adults (8.5%), and male adults (4.8%).
Healthcare providers and patients are focusing on cognitive behavior therapy (CBT) and mindfulness-based approaches to foster a long-term management of depression and other mental health issues.Popularity of Tech-based Mental Health Apps also contributing to Low SalesThe study finds that demand for depression drugs is also witnessing a decline as end-users have more coping options at their disposal.
Depression comprises multiple mental health challenges characterized by the absence of positivity, which leads to feelings such as misery, sadness, and anxiety.
Such feelings are normal only if they exist for a short period of time and it becomes a serious condition when the individual feels lost, angry, frustrated, and gloomy very frequently.
Although prevalence of depression has gone up in the last decade, demand for depression drugs has witnessed a decline, as other forms of therapies, notably cognitive behavior therapy (CBT) has gained popularity.Report summary: https://www.factmr.com/report/3215/depression-drugs-marketAccording to a study by the National Institute of Mental Health, over 10 Mn adults in the U.S. suffered from at least one depressive episode with severe results in 2016.
The same study captured that the prevalence of depression is higher among female adults with 8.5% of cases as compared to 4.8% male adults.Increase in the geriatric population and chronic diseases have been the crucial drivers for the growth of depression drugs market.
With the rise in the health consciousness among the consumers, side-effects of the depression drugs are recognized and advanced technologies for the development of drugs with lesser side-effects are being used.
However, the inclination of the consumers towards non-pharmacological therapies like CBT and meditation is likely to beset the growth of the global depression drugs market.North America constitutes the largest share of the global depression drugs market, given the high concentration of established market players, which are focusing on enhancing the efficiency of these drugs.
Depression Drugs Market: IntroductionAccording to the report, the global depression drugs market was valued at US$ 18.9 Bn in 2019 and is projected to expand at a CAGR of ~2% from 2020 to 2030.
Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression.
These include Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), atypical antidepressants, and tricyclic antidepressants.
Rise in prevalence of depression and increase in incidence of depression among the geriatric population is boosting the global depression drugs.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1151 North America dominated the global depression drugs market in 2019.
Depression is the leading cause of disability among people aged between 15 and 44 in the U.S. More than 41,000 suicides are committed every year in the U.S. Depression is one of the most common illnesses among the elderly population.
Increase in number of depression drugs being dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries make these a major channel of distribution.North America to Lead Global MarketThe global depression drugs market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Fact.MR has recently added a new research report on the global Depression Drugs market to its repository.
This report aims to help readers in understanding key technologies as well as product developments in this market during the forecast period of 2018 - 2026.
Analysts at Fact.MR highlight that the global Depression Drugs market will show growth at a prominent CAGR of during the period of analysis.This report intends to offer an in-depth analysis of various important aspects such as opportunities, drivers, challenges, and restraints of the global Depression Drugs market.
In addition to this, it provides detailed data on various key players working in this market together with important data on their diverse business strategies to maintain their prominent market position.The overall share, volume, and other additional important information of important players is also precisely presented in the latest report on the global Depression Drugs market.
Apart from this, readers get a clear idea about emerging players and the competitive landscape of the market for Depression Drugs during the forecast period of 2018 - 2026.
This aside, the report covers important data on strengths, weaknesses, and threats of all important vendors in the global Depression Drugs market.The report on the global Depression Drugs market offers detailed analysis on various activities that impact on the growth of this market.
The latest trending report Global Depression Drugs Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.
The report will assist reader with better understanding and decision making.The key market players for the global Depression Drugs market are listed below: Intellipharmaceutics Pfizer Eli Lilly Astrazeneca Lundbeck Allergan GSK Otsuka Pharmaceutical Takeda NHU Group Shionogi APOTEX Kanghong Pharma HUAHAI OthersClick here to get a FREE Sample Copy of the Depression Drugs Market Research Report @ https://www.decisiondatabases.com/contact/download-sample-27109The Global Depression Drugs Market Report is equipped with market data from 2016 to 2026.
It also evaluates the competitive scenario of the leading players.
The report forecasts sales and revenue from 2021 to 2026.
The detailed sales channel is also covered in the study.COVID-19 Impact Analysis on Depression Drugs marketThe global pandemic COVID-19 has affected the Depression Drugs market directly or indirectly.
The impact study on production, supply, demand and sales provides a holistic approach to the future.Do You Have Any Query Or Report Customization?
